Tom Polen

BD manufactures products that are ubiquitous in healthcare: syringes, needles, IV catheters, blood collection tubes, diagnostic instruments, and medication dispensing systems. When a nurse draws blood, administers a vaccine, or starts an IV, they are very likely using BD products. The company serves virtually every hospital, laboratory, and clinic in the developed world. Polen is executing a strategic portfolio simplification, including the planned spin-off of BD's Biosciences business (flow cytometry and research instruments), which would leave the remaining BD focused on medication delivery, injection systems, and diagnostics. This separation aims to unlock value by creating more focused entities. His key decisions involve the Biosciences separation execution, innovation in smart connected medical devices, pricing and margin management, supply chain optimization, and navigating healthcare spending trends globally.